164 related articles for article (PubMed ID: 27102581)
1. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
[TBL] [Abstract][Full Text] [Related]
2. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
[TBL] [Abstract][Full Text] [Related]
3. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
Juurlink DN; Gomes T; Shah BR; Mamdani MM
Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
[TBL] [Abstract][Full Text] [Related]
5. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
[TBL] [Abstract][Full Text] [Related]
6. The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
Clemens KK; McArthur E; Dixon SN; Fleet JL; Hramiak I; Garg AX
Can J Diabetes; 2015 Aug; 39(4):308-16. PubMed ID: 25840942
[TBL] [Abstract][Full Text] [Related]
7. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
[TBL] [Abstract][Full Text] [Related]
8. Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes.
Wang MT; Huang YL; Lai JH; Lee CH; Wang PC; Pan HY; Lin C; Liou JT; Hsu YJ
Diabetes Care; 2022 May; 45(5):1276-1287. PubMed ID: 35294529
[TBL] [Abstract][Full Text] [Related]
9. The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes.
Tuccori M; Wu JW; Yin H; Majdan A; Azoulay L
Diabetes Care; 2015 Nov; 38(11):2083-9. PubMed ID: 26341130
[TBL] [Abstract][Full Text] [Related]
10. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
[TBL] [Abstract][Full Text] [Related]
11. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
12. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
13. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study.
Gamble JM; Chibrikov E; Twells LK; Midodzi WK; Young SW; MacDonald D; Majumdar SR
Lancet Diabetes Endocrinol; 2017 Jan; 5(1):43-52. PubMed ID: 27865756
[TBL] [Abstract][Full Text] [Related]
14. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
[TBL] [Abstract][Full Text] [Related]
15. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
[TBL] [Abstract][Full Text] [Related]
16. Is gliclazide a sulfonylurea with difference? A review in 2016.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
[TBL] [Abstract][Full Text] [Related]
17. Rates of hypoglycemia in users of sulfonylureas.
van Staa T; Abenhaim L; Monette J
J Clin Epidemiol; 1997 Jun; 50(6):735-41. PubMed ID: 9250272
[TBL] [Abstract][Full Text] [Related]
18. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Huang HK; Yeh JI
Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
[TBL] [Abstract][Full Text] [Related]
19. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
[TBL] [Abstract][Full Text] [Related]
20. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
